Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing ...
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...
Merck has reported positive Phase IIb/III trial data for clesrovimab, its investigational RSV antibody, showing a 60.4% ...
Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...
New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...
Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval ...
Highlights:,Merck & Co Inc's experimental treatment, clesrovimab, has demonstrated positive results in a mid- to late-stage ...
Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the ...
The drug clesrovimab also helped reduce RSV associated hospitalizations by 84.2% compared to placebo, Merck said.
(Corrects headline, paragraph 1 and 2 in Oct. 17 story to show the drug reduced medically attended lower respiratory ...